Lynn Sadowski Mason
Chief Tech/Sci/R&D Officer bij Eterna Therapeutics LLC
Profiel
Lynn Sadowski Mason is currently the Executive Vice President-Clinical Operations at Eterna Therapeutics LLC.
Prior to this, she held the position of Head-Strategy & Global Clinical Operations at Bristol Myers Squibb Co. from 2015 to 2017.
She also served as the Head-Operations at IRX Therapeutics, Inc. Additionally, Ms. Mason was the Executive Vice President-Clinical Development at Eterna Therapeutics, Inc. from 2019 to 2021.
She completed her undergraduate degree at Indiana University and her graduate degree at Massachusetts College of Pharmacy & Health Science.
Actieve functies van Lynn Sadowski Mason
Bedrijven | Functie | Begin |
---|---|---|
Eterna Therapeutics LLC
Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The private company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | Chief Tech/Sci/R&D Officer | 01-11-2018 |
Eerdere bekende functies van Lynn Sadowski Mason
Bedrijven | Functie | Einde |
---|---|---|
ETERNA THERAPEUTICS INC. | Corporate Officer/Principal | 25-03-2021 |
BRISTOL-MYERS SQUIBB COMPANY | Chief Tech/Sci/R&D Officer | 01-05-2017 |
IRX Therapeutics, Inc.
IRX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology IRX Therapeutics, Inc. provides pharmaceutical products. Its therapies are designed to target and restore the immune system in order to improve a patient's response to next-generation cancer vaccines and novel targeted therapeutics. The company was founded in 1994 and is headquartered in New York, NY. | Chief Operating Officer | - |
Opleiding van Lynn Sadowski Mason
Indiana University | Undergraduate Degree |
Massachusetts College of Pharmacy & Health Science | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
ETERNA THERAPEUTICS INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
IRX Therapeutics, Inc.
IRX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology IRX Therapeutics, Inc. provides pharmaceutical products. Its therapies are designed to target and restore the immune system in order to improve a patient's response to next-generation cancer vaccines and novel targeted therapeutics. The company was founded in 1994 and is headquartered in New York, NY. | Health Technology |
Eterna Therapeutics LLC
Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The private company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | Health Technology |